文献速递神经肿瘤

≥65岁Koos IV级前庭神经鞘瘤的立体定向放射外科治疗:一项多机构回顾性研究

Stereotactic radiosurgery for Koos grade IV vestibular schwannoma in patients ≥ 65 years old: a multi-institutional retrospective study.
PubMed 文献 · Acta Neurochir (Wien) · 2022-12-22

这项多中心回顾性研究纳入150例≥65岁、接受初次单次立体定向放射外科(SRS)治疗的Koos IV级前庭神经鞘瘤患者,随访至少12个月。5年和10年局部肿瘤控制率分别为96.0%和86.2%,5年和10年面部神经功能保留或改善率分别为98.7%和91.0%。作者认为对于经选择的≥65岁Koos IV级患者,SRS可作为手术的安全替代方案,但需进一步随访。

要点

  • 150例≥65岁Koos IV级前庭神经鞘瘤患者接受单次SRS,中位处方剂量12.0 Gy(IQR 1.4)。
  • 5年和10年局部肿瘤控制率分别为96.0%和86.2%,早期肿瘤膨胀发生率6.7%。
  • 5年和10年面部神经功能保留或改善率分别为98.7%和91.0%,三叉神经功能恶化者占5.3%。

核心结论

  • 对于经选择的≥65岁Koos IV级前庭神经鞘瘤患者,SRS可作为手术的安全替代方案。
  • 原文结论指出需进一步随访。

研究设计与样本

  • 多中心回顾性研究,纳入≥65岁、接受初次单次SRS治疗的Koos IV级前庭神经鞘瘤患者,随访至少12个月。
  • 排除有危及生命或致残症状的患者。
  • 共纳入150例患者,中位年龄71.0岁(IQR 9.0),中位肿瘤体积8.3 cc(IQR 4.4),中位处方剂量12.0 Gy(IQR 1.4)。

主要发现

  • 5年和10年局部肿瘤控制率分别为96.0%和86.2%。
  • 早期肿瘤膨胀发生率为6.7%,其中40%有症状。
  • SRS前可服务听力为16.1%,末次随访(中位46.5个月,IQR 55.8)时为7.4%;5年和10年 actuarial 可服务听力保留率分别为69.3%和50.9%。
  • 5年和10年面部神经功能保留或改善率分别为98.7%和91.0%。
  • 末次随访时三叉神经功能改善者占14.0%、稳定者占80.7%、恶化者占5.3%;放射性不良反应(ARE)发生率为12.7%,新发脑积水发生率为8.0%。

临床怎么用

  • 作者认为对于经选择的≥65岁Koos IV级前庭神经鞘瘤患者,SRS可作为手术的安全替代方案。
  • 原文结论指出需进一步随访。

局限性

  • 原文结论指出需进一步随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Surgery is the preferred treatment for large vestibular schwannomas (VS). Good tumor control and cranial nerve outcomes were described in selected Koos IV VS after single-session stereotactic radiosurgery (SRS), but outcomes in elderly patients have never been specifically studied. The aim of this study is to report clinical and radiological outcomes after single-session SRS for Koos IV VS in patients ≥ 65 years old. METHOD: This multicenter, retrospective study included patients ≥ 65 years old, treated with primary, single-session SRS for a Koos IV VS, and at least 12 months of follow-up. Patients with life-threatening or incapacitating symptoms were excluded. Tumor control rate, hearing, trigeminal, and facial nerve function were studied at last follow-up. RESULTS: One-hundred and fifty patients (median age of 71.0 (IQR 9.0) years old with a median tumor volume of 8.3 cc (IQR 4.4)) were included. The median prescription dose was 12.0 Gy (IQR 1.4). The local tumor control rate was 96.0% and 86.2% at 5 and 10 years, respectively. Early tumor expansion occurred in 6.7% and was symptomatic in 40% of cases. A serviceable hearing was present in 16.1% prior to SRS and in 7.4% at a last follow-up of 46.5 months (IQR 55.8). The actuarial serviceable hearing preservation rate was 69.3% and 50.9% at 5 and 10 years, respectively. Facial nerve function preservation or improvement rates at 5 and 10 years were 98.7% and 91.0%, respectively. At last follow-up, the trigeminal nerve function was improved in 14.0%, stable in 80.7%, and worsened in 5.3% of the patients. ARE were noted in 12.7%. New hydrocephalus was seen in 8.0% of patients. CONCLUSION: SRS can be a safe alternative to surgery for selected Koos IV VS in patients ≥ 65 years old. Further follow-up is warranted.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Dumot C, Pikis S, Mantziaris G, et al. Stereotactic radiosurgery for Koos grade IV vestibular schwannoma in patients ≥ 65 years old: a multi-institutional retrospective study. Acta Neurochir (Wien). 2022. PMID: 36543963. doi:10.1007/s00701-022-05454-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。